title: Epigenetic therapies move into new territory, but how exactly do they work?
authors.forename: Rabiya S
authors.initials: RS
authors.lastname: Tuma
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000627:therapeutic use; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000494:pharmacology* / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors; D000077209:Decitabine; D004357:Drug Synergism; D000071221:Enhancer of Zeste Homolog 2 Protein; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D063151:Polycomb Repressive Complex 2; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D014183:Transplantation, Heterologous
chemical_list: D000964:Antimetabolites, Antineoplastic; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D014157:Transcription Factors; D000077209:Decitabine; D015254:DNA Modification Methylases; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D001374:Azacitidine